Bringing RNA therapies full circle with transient CAR T A new in vivo approach programs patients’ T cells directly, bypassing complex manufacturing and expanding access to CAR T therapies.

https://www.drugdiscoverynews.com/bringing-rna-therapies-full-circle-with-transient-car-t-17082 Chimeric antigen receptor (CAR) T cell therapies have transformed treatment paradigms in oncology and are now showing promise in autoimmune diseases. But despite their clinical impact, today’s approved CAR T therapies remain constrained by a complex, ex vivo manufacturing model. T cells must be harvested from each patient, genetically engineered outside the body, expanded, and reinfused — an approach that is costly, time-intensive, and available only at highly specialized centers.